News articles about Edap Tms (NASDAQ:EDAP) have trended somewhat negative this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Edap Tms earned a news sentiment score of -0.05 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 45.1210853640142 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Edap Tms (NASDAQ:EDAP) traded down $0.06 during mid-day trading on Friday, reaching $2.65. The company had a trading volume of 27,450 shares, compared to its average volume of 64,421. The company has a market cap of $76.84, a price-to-earnings ratio of -33.12 and a beta of 1.02. Edap Tms has a twelve month low of $2.25 and a twelve month high of $3.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.96 and a quick ratio of 2.35.
Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings data on Wednesday, November 15th. The medical equipment provider reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02). The business had revenue of $8.44 million for the quarter, compared to analyst estimates of $11.05 million. Edap Tms had a positive return on equity of 7.85% and a negative net margin of 5.36%. The business’s quarterly revenue was down 5.6% compared to the same quarter last year. sell-side analysts anticipate that Edap Tms will post -0.01 earnings per share for the current fiscal year.
A number of research firms have recently commented on EDAP. Zacks Investment Research cut Edap Tms from a “buy” rating to a “hold” rating and set a $3.25 price target for the company. in a report on Wednesday, January 3rd. ValuEngine lowered Edap Tms from a “hold” rating to a “sell” rating in a research report on Sunday, December 31st. Finally, HC Wainwright restated a “buy” rating and set a $6.50 price objective on shares of Edap Tms in a research report on Wednesday, November 22nd.
About Edap Tms
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.